Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic scopolamine butyl for prevention of death rattle in the dying phase
NL-OMON47094Phase 3Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of hyoscine butylbromide (2 arms), sponsored by Erasmus MC. Primary endpoint: Development of clinically significant death rattle. Started Apr 2017; status: active, not recruiting.
02
Drugs
hyoscine butylbromide
Beyond the preview
Go deeper on NL-OMON47094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47094.